Sensex Trades Marginally Up; Healthcare & PSU Stocks Gain

Thu, 2 Nov 11:30 am

   Previous Close   

   Pre-Open   

   09:30 am   

   01:30 pm   

   Closing   

Indian share markets continue to trade flat with a positive bias during the morning trade. Gains are largely seen in stocks from healthcare sector and PSU sector. Meanwhile, metal stocks and FMCG stocks are trading in the red.

The BSE Sensex is trading higher by 46 points and the NSE Nifty is trading higher by 6 points. The BSE Mid Cap index and the BSE Small Cap index are trading up by 1% & 0.8% respectively. The rupee is trading at 64.77 to the US$.

In the news from IPO space, Khadim India has hit the primary markets with its Rs 5.4-billion initial public offering for subscription with a price band of Rs 745-750 per share.

The IPO comprises of fresh issue of aggregating up to Rs 0.5 billion and an offer for sale of up to 6.6 million equity shares. Khadim India has allocated shares worth Rs 1.6 billion to 13 anchor investors at the upper end of the Rs 745 - 750 price band set for the IPO.

The offer for sale comprises of up to 0.7 million shares by promoter Siddhartha Roy Burman and 5.9 million shares by Fairwinds Trustees Services Private Limited.

Meanwhile, IPO of New India Assurance Company was oversubscribed 1.03 times so far on the first day of the three-day bidding on Wednesday.

The IPO, which aims to raise Rs 96 billion, received bids for 123.1 million shares against the total issue size of 120 million shares.

Further, IPO of Mahindra Logistics was subscribed 1.32 times on the second day of offer on Wednesday. The IPO, which aims to raise Rs 8.3 billion, received bids for 18 million shares against the total issue size of 13.6 million shares.

So, are these companies leaving enough money on the table for investors? We've released our IPO notes for the above IPOs. You can access the same in our IPO section.

IPOs are all the rage in the share markets these days. With new companies listing by the day, all with promises of superior returns.

However, we don't need thousands of IPOs to get rich. That's not how super investors make their fortunes. But a few good IPOs could certainly become the multibaggers in your portfolio in a few years.

We have reviewed each of them and have released their recommendation notes. You can check the same on their IPO page.

Download this FREE report now and discover How to Get Rich with IPOs. This guide will show you how to safely profit from the 2017 IPO rush.

Moving on to the news from pharma sector. Five Indian generic drugmakers have been reportedly named in a lawsuit by 45 US states over price-fixing conspiracy, adding to their existing woes like regulator inspections and pricing pressures in their largest market.

The five companies which are charged mainly for keeping prices of the generic drugs exceptionally high include -- Dr Reddy's Laboratories, Sun Pharmaceuticals, Emcure Pharmaceuticals, Zydus Cadila Pharmaceuticals and Glenmark Pharmaceuticals, the reports noted.

Reportedly, the drugmakers and executives divided customers for their drugs among themselves, agreeing that each company would have a certain percentage of the market. The companies sometimes agreed on price increases in advance.

In the expanded complaint, the states allege multiple illegal agreements to fix prices, artificially inflated and/or maintained prices, and reduced competition in the generic drug industry, involving certain diabetes, hypertension, antibiotics and asthma drugs.

The generic drug market was conceived as a way to help bring down the cost of prescription medications for American consumers. For years, though, those saving have not been realised, and instead the prices of many generic drugs have sky-rocketed.

Speaking of blips, the BSE Healthcare Index has been going through more than a blip.

Price to Earnings Ratio (PE) of Top Pharma Companies

Domestic and export markets have both been challenging. Government regulations on branded generics have proved a roadblock in domestic markets. In developed markets, stringent USFDA checks on manufacturing plants along with price erosion in generics have eroded profitability.

There is a structural change taking place in the sector overall as to how business is done and will be done in the future. The pharma sector always traded at premium valuations in the past. It was labeled an 'evergreen' sector. Any small blip was considered an opportunity to buy.

It's important to understand every business has its ups and downs. This is where valuations can help. Here's what Kunal Thanvi, our research analyst, recently wrote about the sector:

• "Pharma companies which can adapt to these changes will thrive in the long run. The uncertainties highlight it important to be stock specific in the sector. It is crucial to look for companies with the competence and staying power to overcome the challenges."

So, what is key to identifying potential multibagger stocks? How does one pick them at the right time and ride them to their full potential? How many multibaggers do you really need to achieve the big riches that you desire?

Most importantly, are there any stocks right now that could turn out to be multibaggers? Click here to know everything that you need to know right now about mutlibagger stocks...

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

Read the latest Market Commentary

Top Gainers TodayTop Gainers over 1-WeekTop Gainers over 1-MonthTop Gainers over 1-YearTop Gainers over 3-YrsTop Gainers over 5-YrsTop Losers TodayTop Losers over 1-WeekTop Losers over 1-MonthTop Losers over 1-YearTop Losers over 3-YrsTop Losers over 5-YrsOnly BuyersOnly SellersMost Active StocksMost Popular Stocks52 Week High Stocks52 Week Low Stocks

INDICESBSE (Rs 0 to 1)BSE (Rs 1 to 2)BSE (Rs 2 to 4)BSE (Rs 4 to 10)BSE (Rs 10 to 20)BSE (Above Rs 20)BSE - AllBSE-30BSE-100BSE-200BSE-500BSE AutoBSE BankexBSE Capital GoodsBSE Consumer DurablesBSE FMCGBSE HealthcareBSE ITBSE MetalBSE Oil & GasBSE PSUBSE TeckBSE RealtyBSE PowerBSE A GroupBSE B GroupBSE Mid-CapBSE Small-CapBSE Basic MaterialsBSE Consumer DiscretionaryBSE IndustrialsBSE UtilitiesBSE Sensex 50BSE Sensex Next 50BSE Bharat 22BSE 150 MidCapBSE 250 SmallCapBSE 250 LargeMidCapBSE 400 MidSmallCapBSE AllCapBSE LargeCapBSE SmallCap SelectBSE 100 LargeCap TMCBSE InfraBSE ManufacturingBSE CPSEBSE Private BankBSE Diversified FinancialsBSE MomentumBSE Low VolatilityBSE QualityBSE Enhanced ValueBSE Divident StabilityS&P BSE IPOBSE SMEIPOBSE 100 ESGBSE CarbonexBSE GreenexNSE (Rs 0 to 10)NSE (Rs 10 to 20)NSE (Above Rs 20)NSE - AllNSE-50NSE ITNSE Nifty Midcap 50NSE JR. NiftyNSE Bank NiftyNIFTY Next 50NIFTY 100NIFTY 200NIFTY 500NIFTY MidCap 100NIFTY SmallCap 250NIFTY SmallCap 50NIFTY SmallCap 100NIFTY LargeMidCap 250NIFTY MidSmallCap 400NIFTY AutoNIFTY Consumer DurablesNIFTY FinanceNIFTY FMCGNIFTY MediaNIFTY MetalNIFTY PharmaNIFTY Private BankNIFTY PSU BankNIFTY RealtyNIFTY Oil & GasNIFTY SME EmergeNIFTY CommoditiesNIFTY CPSENIFTY EnergyNIFTY India ConsumptionNIFTY InfraNIFTY MNCNIFTY PSENIFTY Serv SectorNIFTY100 Liquid 15NIFTY Midcap Liquid 15NIFTY Midcap 150 Quality 50NIFTY50 Equal WeightNIFTY100 Equal WeightNIFTY100 Low Volatility 30NIFTY100 Alpha 30NIFTY Alpha 50NIFTY Dividend Opportunities 50NIFTY High Beta 50NIFTY Low Volatility 50NIFTY200 Quality 30NIFTY 500 Value 50NIFTY 100 Quality 30SECTORSAgricultureAirlinesAluminiumAsset Management CompaniesAutomobilesAuto AncillariesBanks (Private)Banks (PSU)BankingCementChemicalsDefenceDiagnosticsDronesEngineeringElectric VehicleElectric Vehicle BatteryEnergy SourcesESGEthanolFertilizersFintechFMCGFoodGreen HydrogenHotelsInfrastructureInsuranceInvestment and FinanceInvITIT (Large)IT (Others)LogisticsMediaMetalMiningIndia's Big Tech StocksIndian PharmaMNC PharmaPSUPaintPaperPlasticPowerRating AgenciesReal EstateREITsRenewable EnergyRetailingSemiconductorShippingSteelSugarSupply ChainTelecomTextilesTravel Support Services

10 results 25 results 50 results 100 results All results

Indian Share Market Update: Top Gainers and Losers